Kid Risk, Inc., 10524 Moss Park Rd., Ste. 204-364, Orlando, FL 32832, USA.
Expert Rev Vaccines. 2014 Feb;13(2):221-34. doi: 10.1586/14760584.2014.864563. Epub 2013 Dec 4.
Achieving the goal of a world free of poliomyelitis still requires significant effort. Although polio immunization represents a mature area, the polio endgame will require new tools and strategies, particularly as national and global health leaders coordinate the cessation of all three serotypes of oral poliovirus vaccine and increasingly adopt inactivated poliovirus vaccine (IPV). Poliovirus epidemiology and the global options for managing polioviruses continue to evolve, along with our understanding and appreciation of the resources needed and the risks that require management. Based on insights from modeling, we offer some perspective on the current status of plans and opportunities to achieve and maintain a world free of wild polioviruses and to successfully implement oral poliovirus vaccine cessation. IPV costs and potential wastage will represent an important consideration for national policy makers. Innovations may reduce future IPV costs, but the world urgently needs lower-cost IPV options.
实现无脊髓灰质炎世界的目标仍需要付出巨大努力。虽然脊髓灰质炎免疫是一个成熟的领域，但在脊髓灰质炎终结阶段将需要新的工具和策略，特别是在国家和全球卫生领导人协调停止使用所有三种类型的口服脊髓灰质炎疫苗并越来越多地采用脊髓灰质炎灭活疫苗（IPV）的时候。脊髓灰质炎病毒的流行病学和管理脊髓灰质炎病毒的全球选择在不断发展，我们对所需资源的理解和认识以及需要管理的风险也在不断发展。根据建模的见解，我们对实现和维持无野生脊髓灰质炎病毒的世界以及成功实施口服脊髓灰质炎疫苗停用的计划和机会现状提供了一些看法。IPV 的成本和潜在浪费将是国家决策者的一个重要考虑因素。创新可能会降低未来的 IPV 成本，但世界迫切需要更廉价的 IPV 选择。
